Table 3.
Analysis of an angiogenesis RT-PCR gene expression array following AngII low and high dose stimulation of rat microvascular endothelial cells.
| Gene | Protein Annotation | Fold Change* | p-value | Signaling Pathway Involvement* |
|---|---|---|---|---|
| LOW | ANGII | |||
| Cdc42 | Cell division control protein 42 homolog (CDC42) | 1.26 | 0.028 | Rho GTPase, p21 signaling |
| Hif1a | Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) | 1.17 | 0.020 | Master regulator of hypoxia response |
| Mapk13 | Mitogen-activated protein kinase 11 (MAPK13) | 4.83 | 0.026 | p38 MAPK, ATF2(+), ELK1(+), PRKD1(−) signaling |
| Pdgfc | Platelet derived growth factor C | 1.31 | 0.016 | proliferation(+), migration(+), cell survival(+) signaling |
| Pik3r1 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit |
1.39 | 0.007 | insulin(+), FGF, KIT, PDGF signaling |
| Ppp3cb | Calcineurin subunit B type 2 (CANB2) | 1.15 | 0.047 | calcium signaling |
| Prkcb | Protein kinase C beta (PKCβ) | 1.47 | 0.019 | calcium(+), DAG(+), NF-κB(+), ANDR(+), RAF/MAP/ERK(+) signaling |
| Rac1 | Ras-related C3 botulinum toxin substrate 1 | 1.23 | 0.022 | Rho GTPase signaling |
| HIGH | ANGII | |||
| Akt1 | V-akt murine thymomavival oncogene homolog 1 | −3.68 | 0.019 | PDGF(+), cell survival, angiogenesis, insulin signaling |
| Akt2 | V-akt murine thymomavival oncogene homolog 2 | −4.83 | 0.015 | PDGF(+), cell survival, angiogenesis, insulin signaling |
| Arnt | Aryl hydrocarbon receptor nuclear translocator | −2.61 | 0.040 | transport ligand to nucleus |
| Bad | Bcl2 associated agonist of cell death | −4.16 | 0.037 | apoptosis(+) signaling |
| Cdc42 | Cell division control protein 42 homolog (CDC42) | 1.46 | 0.014 | Rho GTPase, p21 signaling |
| Flt-4 | Vascular Endothelial Growth Factor Receptor 4 (VEGFR1) | −5.97 | 0.050 | VEGF(+), PLCG(+), PKC(+), MAPK/ERK(+), AKT1(+) signaling |
| Map2k1 | Dual specificity mitogen-activated protein kinase kinase 1 | −4.74 | 0.009 | MAPK/ERK(+) signaling |
| Mapk11 | Mitogen-activated protein kinase 11 (MAPK11) | −13.02 | 0.005 | p38MAKP(+) signaling |
| Mapk14 | Mitogen-activated protein kinase 14 (MAPK14) | −2.52 | 0.009 | p38MAKP(+) signaling |
| Mapkapk2 | Mitogen-activated protein kinase-activated protein kinase 2 | −2.37 | 0.045 | p38MAPK/MAPK14(+), TNFα(+), HSP27(+) signaling |
| Mapkapk3 | Mitogen-activated protein kinase-activated protein kinase 3 | −4.73 | 0.018 | p38MAPK/MAPK14(+), TNFα(+), ERK(+), JNK(+) signaling |
| Nrp2 | Neuropilin 2 | −3.07 | 0.018 | VEGF(+), PLGF-2(+) signaling |
| Pgf | Placental Growth Factor (PGF) | −8.12 | 0.002 | FLT-1(+) signaling |
| Pik3cb | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PI3K beta isoform) |
−2.03 | 0.024 | PIP3(+), AKT1(+), PDPK1(+) signaling |
| Pik3cd | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3K delta isoform) |
−5.74 | 0.013 | PIP3(+), AKT1(+), PDPK1(+), RAS(+), MAPK/ERK(+), PI3K(+) signaling |
| Pik3r2 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit |
−4.25 | 0.020 | PIP3(+), AKT1(+), PDPK1(+), p110 signaling |
| Pla2g2f | Phospholipase A2, group IIF | −3.80 | 0.009 | hydrolyzes phosphadylglycerol |
| Pla2g4b | Phospholipase A2, group IVB | −2.27 | 0.015 | hydrolyzes glycerophospholipids |
| Pla2g6 | Phospholipase A2, group VI (cytosolic, calcium- independent) |
−12.40 | 0.008 | arachidonic acid release, apoptosis |
| Plcg1 | Phospholipase C, gamma 1 | −5.11 | 0.013 | IP3(+), DAG(+) signaling |
| Ppp3ca | Calcineurin subunit B type 2 (CANB2) | 3.88 | 0.022 | Calcium, DNM1L, HSPB1, SSH1 signaling |
| Prkca | Protein kinase C alpha (PKCα) | −6.34 | 0.003 | RAF1, BCL2, CSPG4, TNNT2/CTNT, MAPK/ERK(+) signaling |
| Prkcg | Protein kinase C gamma (PKCγ) | −7.12 | 0.025 | calcium, DAG, p53/TP53 signaling |
Note: All genes indicated significant fold change in gene expression (p≤0.05); biologic processes include but are not limited to those above (N=3).
*
Indicates 100 nM Ang-(1-7) stimulated versus unstimulated endothelial cells.